Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1997-09-16
1999-11-16
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
A61K 3800
Patent
active
059858303
ABSTRACT:
In accordance with the present invention, there are provided methods for the treatment of polycystic kidney disease and related indications in mammals, employing IGF-I as the active agent. In accordance with another embodiment of the present invention, it has been discovered that IGF-I is an effective agent for the treatment of renal dysplasias and/or renal hypoplasias in mammals. In accordance with yet another embodiment of the present invention, it has been discovered that IGF-I is an effective agent for enhancing glomerular development in mammals. In accordance with still another embodiment of the present invention, it has been discovered that IGF-I is an effective agent for enhancing kidney development in mammals suffering from chronic organ injury.
REFERENCES:
patent: 5565428 (1996-10-01), Clark et al.
Acott Philip D.
Crocker John F. S.
Dalhousie University
Henley III Raymond
Learn June M.
Reiter Stephen E.
LandOfFree
Use of IGF-I for the treatment of kidney disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of IGF-I for the treatment of kidney disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of IGF-I for the treatment of kidney disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1324753